論文

2020年

Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model.
Zhao M, Tazumi A, Takayama S, Takenaka-Ninagawa N, Nalbandian M, Nagai M, Nakamura Y, Nakasa M, Watanabe A, Ikeya M, Hotta A, Ito Y, Sato T, Sakurai H.
Stem Cell Reports. 2020 Jun 23: S2213-6711(20)30225-3. doi: 10.1016/j.stemcr.2020.06.004. Online ahead of print.

Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.
Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, Hotta A.
Nat Commun. 2020 Mar 13;11(1):1334. doi: 10.1038/s41467-020-14957-y

2019年

A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
Yoshida T, Jonouchi T, Osafune K, Takita J, Sakurai H.
Front Cell Dev Biol. 2019 Nov 29;7:316. doi: 10.3389/fcell.2019.00316. eCollection 2019.

Genome-wide microhomologies enable precise template-free editing of biologically relevant deletion mutations.
Grajcarek J, Monlong J, Nishinaka-Arai Y, Nakamura M, Nagai M, Matsuo S, Lougheed D, Sakurai H, Saito MK, Bourque G, Woltjen K.
Nat Commun. 2019 Oct 24;10(1):4856. doi: 10.1038/s41467-019-12829-8

Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells.
Takada H, Kaieda A, Tawada M, Nagino T, Sasa K, Oikawa T, Oki A, Sameshima T, Miyamoto K, Miyamoto M, Kokubu Y, Tozawa R, Sakurai H, Saito B.
J Med Chem. 2019 Oct 24;62(20):9175-9187. doi: 10.1021/acs.jmedchem.9b01100. Epub 2019 Oct 7.

iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases.
Lin CY, Yoshida M, Li LT, Ikenaka A, Oshima S, Nakagawa K, Sakurai H, Matsui E, Nakahata T, Saito MK.
JCI Insight. 2019 Sep 19;4(18). pii: 124299. doi: 10.1172/jci.insight.124299.

Core Transcription Factors Promote Induction of PAX3-Positive Skeletal Muscle Stem Cells.
Sato T, Higashioka K, Sakurai H, Yamamoto T, Goshima N, Ueno M, Sotozono C.
Stem Cell Reports. 2019 Aug 13;13(2):352-365. doi: 10.1016/j.stemcr.2019.06.006. Epub 2019 Jul 25

Human Skeletal Muscle Cells Derived from the Orbicularis Oculi Have Regenerative Capacity for Duchenne Muscular Dystrophy.
Yamanaka Y, Takenaka N, Sakurai H, Ueno M, Kinoshita S, Sotozono C, Sato T.
Int J Mol Sci. 2019 Jul 14;20(14). pii: E3456. doi: 10.3390/ijms20143456.

RNA Virus-Based Episomal Vector with a Fail-Safe Switch Facilitating Efficient Genetic Modification and Differentiation of iPSCs.
Komatsu Y, Takeuchi D, Tokunaga T, Sakurai H, Makino A, Honda T, Ikeda Y, Tomonaga K.
Mol Ther Methods Clin Dev. 2019 May 28;14:47-55. doi: 10.1016/j.omtm.2019.05.010. eCollection 2019 Sep 13

Phenotypic drug screening for dysferlinopathy using patient-derived induced pluripotent stem cells.
Kokubu Y, Nagino T, Sasa K, Oikawa T, Miyake K, Kume A, Fukuda M, Fuse H, Tozawa R, Sakurai H.
Stem Cells Transl Med. 2019 Oct;8(10):1017-1029. doi: 10.1002/sctm.18-0280. Epub 2019 Jun 28.

In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells.
Nakajima T, Sakurai H, Ikeya M.
J Vis Exp. 2019 Apr 25;(146). doi: 10.3791/59359

2018年

Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy.
Lee JJA, Maruyama R, Duddy W, Sakurai H, Yokota T.
Mol Ther Nucleic Acids. 2018 Dec 7;13:596-604. doi: 10.1016/j.omtn.2018.10.004. Epub 2018 Oct 11.

Modeling human somite development and fibrodysplasia ossificans progressiva with induced pluripotent stem cells.
Nakajima T, Shibata M, Nishio M, Nagata S, Alev C, Sakurai H, Toguchida J, Ikeya M.
Development. 2018 Aug 23;145(16). pii: dev165431. doi: 10.1242/dev.165431

A Patient-derived iPSC Model Revealed Oxidative Stress Increases Facioscapulohumeral Muscular Dystrophy-causative DUX4.
Sasaki-Honda M, Jonouchi T, Arai M, Hotta A, Mitsuhashi S, Nishino I, Matsuda R, Sakurai H.
Hum Mol Genet. 2018 Dec 1;27(23):4024-4035. doi: 10.1093/hmg/ddy293.

Recapitulation of Extracellular LAMININ Environment Maintains Stemness of Satellite Cells In Vitro.
Ishii K, Sakurai H, Suzuki N, Mabuchi Y, Sekiya I, Sekiguchi K, Akazawa C.
Stem Cell Reports. 2018 Jan 10. pii: S2213-6711(17)30561-1.
doi: 10.1016/j.stemcr.2017.12.013.

Cell Membrane Repair Assay Using a Two-photon Laser Microscope.
Lee JJA, Maruyama R, Sakurai H, Yokota T.
J Vis Exp. 2018 Jan 2;(131). doi: 10.3791/56999.

2017年

A human iPS cell myogenic differentiation system permitting high-throughput drug screening.
Uchimura T, Otomo J, Sato M, Sakurai H.
Stem Cell Res. 2017 Dec;25:98-106. doi: 10.1016/j.scr.2017.10.023. Epub 2017 Oct 28

A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.
Yoshida T, Awaya T, Jonouchi T, Kimura R, Kimura S, Era T, Heike T, Sakurai H.
Scientific Reports. 2017 Oct 18;7(1):13473. doi: 10.1038/s41598-017-14063-y.

Myogenic Differentiation from MYOGENIN-Mutated Human iPS Cells by CRISPR/Cas9.
Higashioka K, Koizumi N, Sakurai H, Sotozono C, Sato T.
Stem Cells Int. 2017;2017:9210494.

Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability
Ueki J, Nakamori M, Nakamura M, Nishikawa M, Yoshida Y, Tanaka A, Morizane A, Kamon M, Araki T, Takahashi M.P., Watanabe A, Inagaki N, Sakurai H.
Scientific Reports. 2017 Feb 13;7:42522.

2016年

Functional validation and expression analysis of myotubes converted from skin fibroblasts using a simple direct reprogramming strategy.
Horio F, Sakurai H, Ohsawa Y, Nakano S, Matsukura M, Fujii I.
eNeurologicalSci. 2016 Nov 3;6:9-15. doi: 10.1016/j.ensci.2016.11.002. eCollection 2017 Mar. PMID: 29260008

2015年

MicroRNA-494 plays a role in fiber type-specific skeletal myogenesis in human induced pluripotent stem cells.
Iwasaki H, Imamura T, Morino K, Shimosato T, Tawa M, Ugi S, Sakurai H, Maegawa H, Okamura T.
Biochem Biophys Res Commun. 2015 Oct 28. pii: S0006-291X(15)30827-5. doi: 10.1016/j.bbrc.2015.10.128.

Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.
Shoji E., Sakurai H., Nishino T., Nakahata T., Heike T., Awaya T., Fujii N., Manabe Y., Matsuo M., Sehara-Fujisawa A.
Scientific Reports. 2015 :5, Article number: 12831; doi:10.1038/srep12831

Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9.
Li HL., Fujimoto N., Sasakawa N., Shirai S., Ohkame T., Sakuma T., Tanaka M., Amano N., Watanabe A., Sakurai H., Yamamoto T., Yamanaka S., Hotta A.
Stem Cell Reports. 2015 Jan 13;4(1):143-54.

2014年

Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.
Yasuno T., Osafune K., Sakurai H., Asaka I., Tanaka A., Yamaguchi S., Yamada K., Hitomi H., Arai S., Kurose Y., Higaki Y., Sudo M., Ando S., Nakashima H., Saito T., Kaneoka H.
Biochem Biophys Res Commun. 2014 May 30;448(2):175-81.

2013年

In vitro characterization and engraftment of adipocytes derived from human induced pluripotent stem cells and embryonic stem cells.
Noguchi M., Hosoda K., Nakane M., Mori E., Nakao K., Taura D., Yamamoto Y., Kusakabe T., Sone M., Sakurai H., Fujikura J., Ebihara K., Nakao K..
Stem Cells Dev. 2013 Nov 1;22(21):2895-905.

Fetal skeletal muscle progenitors have regenerative capacity after intramuscular engraftment in dystrophin deficient mice.
Sakai H., Sato T., Sakurai H., Yamamoto T., Hanaoka K., Montarras D., Sehara-Fujisawa A.
PLoS One. 2013 May 9;8(5):e63016

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Myoshi Myopathy in vitro
Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A, Manabe Y, Fujii N, Hanaoka K, Era T, Yamashita S, Isobe K, Kimura E, Sakurai H.
PLoS One. 2013, 8(4):e61540

2012年

In Vitro Modeling of Paraxial Mesodermal Progenitors Derived from Induced Pluripotent Stem Cells
Sakurai H., Sakaguchi Y., Shoji E., Nishino T., Maki I., Sakai H., Hanaoka K., Kakizuka A., Sehara-Fujisawa A
PLoS ONE. 2012,7(10): e47078.

2011年

Differentiation of induced pluripotent stem cells to thymic epithelial cells by phenotype
Inami Y., Yoshikai T., Ito S., Nishio N., Suzuki H., Sakurai H., Isobe K.
Immunology and Cell Biology. 2011, 89, 314-21.

2010年

GADD34 suppresses wound healing by upregulating expression of myosin IIA
Tanaka C, Ito S, Nishio N, Kodera Y, Sakurai H, Suzuki H, Nakao A, Isobe K.
Transgenic Res. 2010 Aug;19(4):637-45.

Metalloprotease-Dependent Onset of Blood Circulation in Zebrafish
Iida A., Sakaguchi K., Sato K., Sakurai H., Nishimura D., Iwaki A., Takeuchi M., Kobayashi M., Misaki K., Yonemura S., Kawahara A., Sehara-Fujisawa A.
Current Biology. 2010 June; 20(12): 1110-16.

2009年以前

Bidirectional induction toward paraxial mesodermal derivatives from mouse ES cells in chemically defined medium
Sakurai H., Inami Y., Tamamura Y., Yoshikai T., Sehara-Fujisawa A., Isobe K.
Stem Cell Research. 2009 Sep-Nov;(2-3): 157-69.

Paraxial mesodermal progenitors derived from mouse embryonic stem cells contribute to muscle regeneration via differentiation into muscle satellite cells
Sakurai H., Okawa Y., Inami Y., Nishio N., Isobe K.
Stem Cells. 2008 Jul;26(7): 1865-73

Neutrophil depletion delays wound repair in aged mice
Nishio N., Okawa Y., Sakurai H., Isobe K.
Age. 2008; 30: 11-19

In vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility
Sakurai H., Era T., Lakt LM., Okada M., Nakai S., Nishikawa S., Nishikawa SI.
Stem Cells. 2006 Mar;24(3): 575-86

Characterization of mesendoderm: a diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture
Tada S., Era T., Furusawa C., Sakurai H., Nishikawa S., Kinoshita M., Chiba T., Nishikawa SI.
Development. 2005 Oct;132(19): 4363-74

プロトコール

In Vitro Evaluation of Exon Skipping in Disease-Specific iPSC-Derived Myocytes.
Zhao M, Shoji E, Sakurai H.
Methods Mol Biol. 2018;1828:173-189. doi: 10.1007/978-1-4939-8651-4_11

Directed Myogenic Differentiation of Human Induced Pluripotent Stem Cells.
Shoji E, Woltjen K, Sakurai H.
Methods in Mol Biol. 2015 May 14.

ヒトiPS細胞から骨格筋細胞への効率的な分化誘導
庄子栄美、櫻井英俊
ES・iPS細胞実験スタンダード(羊土社) 2014:194-201

著作物

1.「多能性幹細胞による筋ジストロフィー治療」
櫻井英俊
生体の科学(医学書院) 62(2), 161-164, 2011

日本語解説

1. iPS細胞を使った筋疾患研究
櫻井英俊
病理と臨床 2015:33(6): 592-598

2. 患者由来iPS細胞による筋疾患モデル作製
櫻井英俊
医学のあゆみ 2015:252(9): 969-975

3. 三好型ミオパチー
櫻井英俊
遺伝子医学MOOK 2015:“27 iPS細胞を用いた難病研究”: 71-76

4. iPS細胞を用いた難治性筋疾患治療研究
櫻井英俊
実験医学2014:32(9):1359-1365

5. iPS細胞創薬は10年以内に実現するか?「Yes」の立場から
櫻井英俊
Frontiers in Parkinson Disease 2014:7(4):200-203

6. iPS細胞を用いた筋疾患モデル
櫻井英俊
最新医学 2014:69: 589-597

7. iPS細胞技術を用いた筋再生療法の開発
櫻井英俊
整形・災害外科 2013:56(5):689-694

8. iPS細胞を用いた筋ジストロフィー症の病態解析
竹中菜々、櫻井英俊
Medical Science Digest 2013:39(11): 514-517

9. iPS細胞を使う―骨格筋の研究へ―
竹中菜々、櫻井英俊
整形外科 2013:64(11): 1221-1223

10. iPS細胞
櫻井英俊、山中伸弥
先進医療 NAVIGATOR 2013: 93-95

11. 多能性幹細胞による筋ジストロフィー治療
櫻井英俊
生体の科学(医学書院)  2011:62(2): 161-164

12. iPS細胞(人工多能性幹細胞)研究
櫻井英俊、山中伸弥
日本臨床 2011:69(12): 2114-18